Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers

Abstract

This was a double-blind, randomised, placebo-controlled, crossover study of the acute cognitive and subjective effects of nabilone 1—3 mg in healthy male volunteers. The Cognitive Drug Research computerised system (CDR system) was used to assess changes in attention, working and episodic memory. In addition, a number of self-ratings were conducted including those of mood, alertness and perceived drug effects. Impairments to attention, working and episodic memory and self-ratings of alertness were evident. Volunteers also experienced a number of subjective drug effects. These data demonstrate that acute doses of nabilone in the range 1—3 mg produce clear cognitive and subjective effects in healthy volunteers, and therefore they may be used as reference data in the future study of peripherally acting cannabinoids believed to be free from such effects.

Keywords

attention CDR system cognition episodic memory nabilone subjective effects working memory

Get full access to this article

View all access options for this article.

References

Ashton, JC , Milligan, ED ( 2008) Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs 9: 65-75.

Beuzen, JN , Taylor, N. , Wesnes, K. , Wood, A. ( 1999) A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers . J Psychopharmacol 13: 152-158.

Bond, A. , Lader, M. ( 1974) The use of visual analogue scales in rating subjective feelings. Br J Med Psychol 80: 1-46.

Chait, LD , Fischman, MW , Schuster, CR ( 1985) ‘Hangover’ effects the morning after marijuana smoking. Drug Alcohol Depend 15: 229-238.

Diana, G. , Malloni, M. , Pieri, M. ( 2003) Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission. Pharmacol Biochem Behav 75: 585-591.

Ebert, U. , Siepmann, M. , Oertel, R. , Wesnes, KA , Kirch, W. ( 1998) Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 38: 720-726.

Frank, B. , Serpell, MG , Hughes, J. , Matthews, JN , Kapur, D. ( 2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336: 199-201.

Gaertner, J. , Radbruch, L. , Giesecke, T. , Gerbershagen, H. , Petzke, F. , Ostgathe, C. , et al. (2006) Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand 50: 664-672.

Glass, RM , Uhlenhuth, EH , Hartel, FW , Schuster, CR , Fischman, MW ( 1981) Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 21: 383S-396S.

10.

Hanks, GW , O’Neill, WM , Simpson, P. , Wesnes, K. ( 1995) The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 48: 455-460.

11.

Hanus, L. , Breuer, A. , Tchilibon, S. , Shiloah, S. , Goldenberg, D. , Horowitz, M. , et al. (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96: 14228-14233.

12.

Herkenham, M. , Lynn, AB , Little, MD , Johnson, MR , Melvin, LS , de Costa, BR , et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87: 1932-1936.

13.

Jhaveri, MD , Sagar, DR , Elmes, SJ , Kendall, DA , Chapman, V. ( 2007) Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 36: 26-35.

14.

Kalant, H. ( 2004) Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28: 849-863.

15.

Klein, TW , Newton, C. , Larsen, K. , Lu, L. , Perkins, I. , Nong, L. , et al. (2003) The cannabinoid system and immune modulation . J Leukoc Biol 74: 486-496.

16.

Kumar, RN , Chambers, WA , Pertwee, RG ( 2001) Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 56: 1059-1068.

17.

Kurzthaler, I. , Bodner, T. , Kemmler, G. , Entner, T. , Wissel, J. , Berger, T. , et al. (2005) The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psycho-pharmacol 20: 291-293.

18.

Lemberger, L. , Rowe, H. ( 1975) Clinical pharmacology of nabilone, a cannabinol derivative . Clin Pharmacol Ther 18: 720-726.

19.

Lorenz, J. , Beck, H. , Bromm, B. ( 1997) Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain 73: 369-375.

20.

Lundqvist, T. ( 2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81: 319-330.

21.

McGilveray, IJ ( 2005) Pharmacokinetics of cannabinoids. Pain Res Manag 10: 15A-22A.

22.

O’Neill, WM , Hanks, GW , White, L. , Simpson, P. , Wesnes, K. ( 1995) The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 48: 447-453.

23.

Pertwee, RG ( 1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129-180.

24.

Pertwee, RG ( 2000) Cannabinoid receptor ligands: clinical and neuro-pharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 9: 1553-1571.

25.

Pertwee, RG ( 2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin . Br J Pharmacol 153: 199- 215.

26.

Piomelli, D. , Giuffrida, A. , Calignano, A. , Rodriguez de Fonseca, F. ( 2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21: 218-224.

27.

Ranganathan, M. , DSouza, DC ( 2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188: 425-444.

28.

Shah, J. , Wesnes, KA , Kovelesky, RA , Henney 3rd, HR ( 2006) Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther 28: 1308-1317.

29.

Van Sickle, MD , Duncan, M. , Kingsley, PJ , Mouihate, A. , Urbani, P. , Mackie, K. , et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329- 332.

30.

Wachtel, SR , Elsohly, MA , Ross, SA , Ambre, J. , de Wit, H. ( 2002) Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology ( Berl) 161: 331-339.

31.

Wesnes, K. , Pincock, C. ( 2002) Practice effects on cognitive tasks: a major problem? Lancet Neurol 1: 473.

32.

Wesnes, K. , Simpson, PM ( 1988) Can scopolamine produce a model of the memory deficits seen in ageing and dementia? In: Gruneberg, MM , Morris, PE , Sykes, RN (eds), Practical Aspects of Memory: Current Research and Issues: Clinical and Educational Implications . Chichester: Wiley, pp. 236-242.

33.

Wesnes, K. , Simpson, PM , Jansson, B. , Grahnen, A. , Weimann, HJ , Kuppers, H. ( 1997) Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Eur J Clin Pharmacol 52: 351- 358.

34.

Wesnes, KA , Garratt, C. , Wickens, M. , Gudgeon, A. , Oliver, S. ( 2000a) Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol 49: 110-117.

35.

Wesnes, KA , Ward, T. , McGinty, A. , Petrini, O. ( 2000b) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 152: 353-361.